Rallybio Corporation
- RLYB
- NASDAQ
- Biotechnology
- Rare Disease Therapeutics
- Monoclonal Antibody Therapies
$16.35
Today +0.43%Quote Oct 19, 2026, 08:00 PM UTC
−4.89%over the last month
Max drawdown −5.5%From 1-month high −5.1%3 months −3.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Rallybio
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
7
Market value
$86.8M
Quote Oct 19
Floor
$16.30
0.3% below price
Resistance
$16.47
0.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about RLYBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free